Sagimet Biosciences (NASDAQ:SGMT) Share Price Crosses Below 50-Day Moving Average – Here’s What Happened

Sagimet Biosciences Inc. (NASDAQ:SGMT – Get Free Report) shares passed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $9.80 and traded as low as $9.58. Sagimet Biosciences shares last traded at $9.62, with a volume of 1,026,665 shares traded.

Analyst Ratings Changes

A number of analysts have recently weighed in on SGMT shares. Oppenheimer boosted their target price on shares of Sagimet Biosciences from $33.00 to $38.00 and gave the stock an “outperform” rating in a report on Thursday, October 1st. Cantor Fitzgerald reissued an “overweight” rating on shares of Sagimet Biosciences in a research note on Thursday, October 1st. Canaccord Genuity Group decreased their price objective on Sagimet Biosciences from $56.00 to $50.00 and set a “buy” rating on the stock in a research report on Friday, November 13th. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Sagimet Biosciences in a research note on Monday, October 5th. Finally, Wells Fargo & Company set a $27.00 price objective on Sagimet Biosciences in a research note on Friday, November 13th. Nine research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Sagimet Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $26.07.

View Our Latest Stock Analysis on SGMT

Sagimet Biosciences Stock Performance

The company has a fifty day simple moving average of $9.77 and a two-hundred day simple moving average of $7.78. The firm has a market capitalization of $564.41 million, a PE ratio of -7.63 and a beta of 3.43.

Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.05). On average, equities analysts anticipate that Sagimet Biosciences Inc. will post -1.26 earnings per share for the current fiscal year.

Institutional Trading of Sagimet Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SGMT. RA Capital Management L.P. purchased a new stake in shares of Sagimet Biosciences in the 3rd quarter valued at $17,784,000. Marshall Wace LLP acquired a new position in shares of Sagimet Biosciences during the 3rd quarter worth approximately $7,433,000. Renaissance Technologies LLC lifted its position in shares of Sagimet Biosciences by 82.6% during the 1st quarter. Renaissance Technologies LLC now owns 625,469 shares of the company’s stock valued at $3,268,000 after buying an additional 282,969 shares in the last quarter. Nantahala Capital Management LLC purchased a new position in shares of Sagimet Biosciences during the 3rd quarter valued at approximately $4,662,000. Finally, Seven Fleet Capital Management LP acquired a new stake in Sagimet Biosciences in the 2nd quarter valued at $3,119,000. Institutional investors and hedge funds own 87.86% of the company’s stock.

About Sagimet Biosciences

(Get Free Report)

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing medicines that target fatty acid synthase (FASN), an enzyme involved in the body’s production of fatty acids. The company is based in San Mateo, California. Its lead drug candidate, denifanstat (also known as TVB-2640), is an oral FASN inhibitor being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. The candidate has also been studied for other conditions. Sagimet is also developing TVB-3567, another FASN inhibitor being investigated as a potential treatment for acne.

See Also

Receive News & Ratings for Sagimet Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sagimet Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.